Interviews of 2023: the longevity companies

Six of our favourite interviews with companies operating at the cutting edge of longevity science.
From cellular reprogramming and SIRT6 to young blood and telomere boosting therapies, there are many different approaches being pursued by longevity companies. And we’ve spoken to them all. Here are some of our favourite interviews from the past year.

Retro: A longevity biotech triple-threat?
Retro Biosciences was founded in 2021 to develop cellular reprogramming, autophagy and plasma-inspired therapeutics, with the goal of increasing healthy human lifespan by 10 years. Earlier this year it was revealed that its $180 million funding was provided by Sam Altman, the CEO of OpenAI.

Speaking about Retro’s multi-pronged approach, founder Joe Betts-LaCroix, told us “As a student of aging biology and having looked at hundreds of papers on the topic over the years, it’s clear to me there are multiple things going on in parallel. And anybody who stands up and says the cause of aging is negative factors of blood or telomeres, or histological entropy caused by a genetic noise or whatever is probably a salesman.”

SIRTLab: Does SIRT6 hold the key to human longevity?

Interviews of 2023: the longevity companies